The purpose of this legislative proposal is to amend the Drug Price Negotiation Program under the Social Security Act. Specifically, it aims to create a more balanced negotiation period for drug prices between two types of medications: small-molecule drugs, which are typically simpler and chemically synthesized, and biologic drugs, which are more complex and derived from living organisms. The key provision of this proposal is the adjustment of the negotiation timeline for drug prices.